Diaceutics x DeepIntent: Physician Segmentation That Brings Real-Time Diagnostic Insight to HCP Engagement

Our partnership with DeepIntent looks to solve age-old challenges pharma marketers experience. We saw an opportunity to combine our solutions, allowing accurate physician segmentation. This data will become available alongside who is evaluating patient conditions and their biomarkers.

The challenges pharma marketers face? They spend years waiting for claims. Waiting for prescriptions. Waiting for signals that confirm a patient has already begun their treatment journey.

But by the time a claim appears, the moment of influence has often already passed.

Diagnosis and testing reveal intent far earlier than traditional commercial datasets. They show who is evaluating a condition today, who is testing for a biomarker now, and which physicians are on the cusp of making a treatment decision. Yet historically, marketing teams haven’t been able to act this early because diagnostic data wasn’t integrated into the tools they use to activate media.

The Diaceutics and DeepIntent partnership aims to change that.

Why Waiting for Claims Is Too Late

Waiting for claims has trained marketers to engage long after clinical decision-making happens. Claims-based targeting is inherently retrospective, often months behind real-world clinical activity.

Acting after the point of decision is not enough. Diseases progress quickly, as are competitive markets and increasingly complex biomarker-driven therapies.

Pharma marketers need accurate physician segmentation tools. That way they can engage physicians upstream. And do so when diagnostic activity first signals treatment intent.

Real-Time Diagnostic Signals, Now Fully Actionable in DeepIntent’s DSP

This partnership combines our AI-driven diagnostic, lab, and genomic insights with DeepIntent’s industry-leading healthcare DSP.

Marketers can plan, activate, and optimize campaigns. They'll have access to more than 100 prebuilt diagnostic and genomic audience segments. These cover chronic diseases, rare diseases, and precision oncology.

This is a fundamental shift in how treatment intent is identified and acted upon.

With diagnostically informed audiences available natively within DeepIntent, brands can:

• Physician segmentation and targeting tools, based on real clinical activity happening today vs months-old claims.
• Close the recency gap by activating campaigns the moment diagnostic or lab triggers occur.
• Identify hidden treaters not visible in claims data but evident in diagnostic patterns.
• Engage physicians earlier. Meaning when influence is still possible, and decisions are still being shaped.

This is the earliest, most actionable view of treatment intent the industry has ever had access to.

Meeting Physicians at the Moment of Decision

'When influence matters most' has always been a guiding principle in HCP marketing. But operationally, marketing teams have been constrained by the timing of traditional datasets.

Now, DeepIntent’s DSP trusted for its healthcare-specific optimization, identity capabilities, and proven script lift becomes the activation engine for real-time clinical intelligence.

This means marketers can reach physicians when a:

• New diagnostic test is ordered
• Biomarker result signals eligibility
• Rare disease evaluation begins
• Treatment decision is imminent

Not after a script is written. Not after a claim hits. But in the moment.

DeepIntent already helps marketers achieve measurable outcomes through real-world clinical signals and privacy-safe optimization at scale. By integrating Diaceutics’ clinical and genomic intelligence, the platform becomes even more powerful.

For marketers, that means:

• Earlier visibility into treatment intent
• New pathways to influence before decisions are locked in
• More accurate audience qualification and physician segmentation for complex precision therapies
• Campaign performance tied to real-world clinical triggers

This is precision medicine marketing operating at the speed of clinical reality.